MX2021010700A - Compuestos utiles en la terapia del vih. - Google Patents

Compuestos utiles en la terapia del vih.

Info

Publication number
MX2021010700A
MX2021010700A MX2021010700A MX2021010700A MX2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A MX 2021010700 A MX2021010700 A MX 2021010700A
Authority
MX
Mexico
Prior art keywords
compounds useful
hiv therapy
hiv
compounds
therapy
Prior art date
Application number
MX2021010700A
Other languages
English (en)
Inventor
John F Miller
B Narasimhulu Naidu
Emile Johann Velthuisen
David Temelkoff
La Rosa Martha Alicia De
Vicente Samano
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip No 2 Ltd filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MX2021010700A publication Critical patent/MX2021010700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Abstract

La presente invención se refiere a compuestos de la Fórmula (I), sales de los mismos, composiciones farmacéuticas de los mismos, así como a métodos para tratar o prevenir el VIH en sujetos.
MX2021010700A 2019-03-06 2020-03-04 Compuestos utiles en la terapia del vih. MX2021010700A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
MX2021010700A true MX2021010700A (es) 2021-10-01

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010700A MX2021010700A (es) 2019-03-06 2020-03-04 Compuestos utiles en la terapia del vih.

Country Status (21)

Country Link
US (2) US20230174534A1 (es)
EP (1) EP3934760A1 (es)
JP (1) JP2022525013A (es)
KR (1) KR20210136052A (es)
CN (1) CN113811360A (es)
AR (1) AR118240A1 (es)
AU (1) AU2020231934B2 (es)
BR (1) BR112021017604A2 (es)
CA (1) CA3132112A1 (es)
CL (1) CL2021002309A1 (es)
CO (1) CO2021012579A2 (es)
CR (1) CR20210460A (es)
EA (1) EA202192433A1 (es)
IL (1) IL285894A (es)
MA (1) MA55200A (es)
MX (1) MX2021010700A (es)
PE (1) PE20212089A1 (es)
SG (1) SG11202109253SA (es)
TW (1) TW202102233A (es)
WO (1) WO2020178767A1 (es)
ZA (1) ZA202106096B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021116872A1 (en) 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
TW202200161A (zh) * 2020-03-20 2022-01-01 美商基利科學股份有限公司 4’-c-經取代-2-鹵基-2’-去氧腺苷核苷之前藥及其製造與使用方法
CN113735862B (zh) * 2020-12-30 2024-02-02 南方科技大学 一种治疗病毒感染的核苷类化合物及其用途
TW202237146A (zh) 2021-01-25 2022-10-01 美商布里生物科學股份有限公司 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
WO2022182604A1 (en) * 2021-02-23 2022-09-01 Viiv Healthcare Company Compounds useful in hiv treatment

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HUP0400241A2 (hu) 2001-03-19 2004-06-28 Ono Pharmaceutical Co., Ltd. Hatóanyagként triaza-spiro[5.5]undekán-származékokat tartalmazó gyógyszerkészítmények
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
WO2016057866A1 (en) * 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
US20170313735A1 (en) * 2014-10-31 2017-11-02 Sandoz Ag Improved Fluorination Process
JP6768796B2 (ja) * 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ４’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
CA3042671A1 (en) * 2016-11-03 2018-05-11 Laurence I. Wu Prodrugs of clofarabine
EP3762396A1 (en) * 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy

Also Published As

Publication number Publication date
CN113811360A (zh) 2021-12-17
AU2020231934A8 (en) 2022-03-24
EA202192433A1 (ru) 2021-12-28
AR118240A1 (es) 2021-09-22
CL2021002309A1 (es) 2022-09-20
WO2020178767A1 (en) 2020-09-10
AU2020231934A1 (en) 2021-09-23
CA3132112A1 (en) 2020-09-10
JP2022525013A (ja) 2022-05-11
US20220411425A1 (en) 2022-12-29
PE20212089A1 (es) 2021-11-04
CO2021012579A2 (es) 2021-10-20
AU2020231934B2 (en) 2023-04-20
BR112021017604A2 (pt) 2021-11-16
TW202102233A (zh) 2021-01-16
ZA202106096B (en) 2023-03-29
MA55200A (fr) 2022-01-12
CR20210460A (es) 2022-02-03
EP3934760A1 (en) 2022-01-12
IL285894A (en) 2021-10-31
US20230174534A1 (en) 2023-06-08
KR20210136052A (ko) 2021-11-16
SG11202109253SA (en) 2021-09-29

Similar Documents

Publication Publication Date Title
EA202091491A1 (ru) Новые бензиламинозамещенные пиридопиримидиноны и производные в качестве ингибиторов sos1
CR20210460A (es) Compuestos útiles en la terapia del vih
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
NZ733174A (en) Quinazoline derivatives used to treat hiv
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2021006156A (es) Compuestos utiles en la terapia para el vih.
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2021001612A (es) Compuestos utiles en terapia del vih.
EA201692260A1 (ru) Соединения 1,3,4-тиадиазола и их применение в лечении рака
MX2021012096A (es) Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo.
MX2018006953A (es) Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
WO2018039077A8 (en) Therapeutic compounds
SG10201907291QA (en) Monomethylfumarate prodrug compositions
TR201819805T4 (tr) Flavaglin türevleri̇.
MX2018016339A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2023000198A (es) Inhibidores de atr y usos de estos.